Episode 41: Pre ASCO Appetizer

Neuro update

INDIGO:

• A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation

• https://meetings.asco.org/abstracts-presentations/219807

 GI Update

Rectal Cancer

·       PROSPECT:

• A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048)

• https://meetings.asco.org/abstracts-presentations/219804\

·       PRODIGE 23- 7 year update:

• Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial

• https://meetings.asco.org/abstracts-presentations/219425

Colon Cancer

·       DESTINY-CRC02:

• Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.

• https://meetings.asco.org/abstracts-presentations/218394

·       NeoCol trial:

• Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial.

• https://meetings.asco.org/abstracts-presentations/219419

Upper GI

Pancreatic

·       NORPACT-1:

• Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1)

• https://meetings.asco.org/abstracts-presentations/219426

·       DIPLOMA:

• Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): An international randomised trial.

• https://meetings.asco.org/abstracts-presentations/218312

Genitourinary

Renal

·       CLEAR: 

• Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

• https://meetings.asco.org/abstracts-presentations/226720

·       CONTACT- 03:

• Atezo plus cabo vs cabozantinib (PFS)

• Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study

• https://meetings.asco.org/abstracts-presentations/219853

·       KEYNOTE-426:

• Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426

• https://meetings.asco.org/abstracts-presentations/219855

Bladder

·       VESPER trial:

• Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.

• https://meetings.asco.org/abstracts-presentations/219854

Prostate

·       PEACE 1 trial:

• Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.

• https://meetings.asco.org/abstracts-presentations/218388 

Lung

·       ADAURA:

• Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).

• https://meetings.asco.org/abstracts-presentations/219805

   KEYNOTE-789:

• Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 

• https://meetings.asco.org/abstracts-presentations/218083

·       Anti-tumour activity of sunvozertinib in NSCLC with EGFR sensitizing mutations after failure of EGFR TKI treatment: - -

• https://meetings.asco.org/abstracts-presentations/218922

·       KEYNOTE-671:

• Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.

• https://meetings.asco.org/abstracts-presentations/225718

  Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): 

• Practice-informing data from a global, phase 3, randomized, controlled trial (RCT)

• https://meetings.asco.org/abstracts-presentations/220377

Breast

·       SONIA:

• Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).

• https://meetings.asco.org/abstracts-presentations/219701

·       NATALEE:

• Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial.

• https://meetings.asco.org/abstracts-presentations/218407

  PHERGain:

• 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC)

• https://meetings.asco.org/abstracts-presentations/219848

·       DESTINY-PanTumor02(DP-02):

• Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.

• Https://meetings.asco.org/abstracts-presentations/220035

·       TROPiCS-020:

• Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).

• Follow up on study of SG in HR+ HER negative breast cancer in patients with 2+ prior lines of therapy

• https://meetings.asco.org/abstracts-presentations/219698

Head and Neck

·       CONTINUUM: 

• Phase 3 study of sintilimab (anti-PD-1) in combination with induction chemotherapy and chemoradiotherapy for patients with T3N0 or T4N0 nasopharyngeal cancer

• IO + chemoRT in early NPC

• https://clinicaltrials.gov/ct2/show/NCT03700476

<iframe style="border-radius:12px" src="https://open.spotify.com/embed/episode/1I7w4kY0i5rQeIlD1TziXB?utm_source=generator" width="100%" height="152" frameBorder="0" allowfullscreen="" allow="autoplay; clipboard-write; encrypted-media; fullscreen; picture-in-picture" loading="lazy"></iframe>